General

Episode 17: Appen’s acquisition, Advance NanoTek, Clinuval Pharmaceuticals and more!

Andrew Page

This week, we dissect Appen’s latest acquisition and touch on the ethics of AI.

We look to why shares in Envirosuite have surged higher, and ask whether the phenomenal gains from Clinuval Pharmaceuticals and Advance NanoTek can continue.

Plus Matt updates us on his recent meeting with the PushPay team.

For more great content, please visit us at www.strawman.com, www.mattjoass.com & www.ethicalequities.com.au

Email us at [email protected]

And find us on Twitter @sage_simian @mattjoass @claudedwalker



Return to the Strawman Platform here

Strawman is Australia’s premier online investment club. Join for free to access independent & actionable recommendations from proven private investors.

Register for free ASX recommendations

This Service provides general financial advice only, and has not taken your personal circumstances into account. Strawman Pty Ltd operates under AFSL 501223 . For more information please see our Terms of use. Please remember that share market investments can go up and down and that past performance is not necessarily indicative of future returns. Strawman Pty Ltd does not guarantee the performance of, or returns on any investment.

© 2019 Strawman Pty Ltd. All rights reserved.

| Privacy Policy | Terms of Service |

ACN: 610 908 211 | Australian Financial Services Licence (AFSL): 501223



Related Articles

General

No one wins all the time

Between 2019 and 2020 Warren Buffett’s Berkshire Hathaway (NYSE:BRK) underperformed the S&P500 by 37%. It was one of the poorer periods of relative performance for the Oracle of Omaha, who was “burdened” with loads of cash and missed out on a lot of the boom in technology stocks. As you can see, Buffett regularly lags the broader index. And sometimes […]

General

Gentrack (ASX:GTK) downgrades guidance

Utilities and airport software specialist Gentrack (ASX:GTK) has today told investors to expect a full year operating profit (EBITDA) of between $27 – $28 million, less than previous guidance which called for a result “marginally ahead of FY18 ($31 million)”. Gentrack said the downgrade was due to delays in customer projects and contracts as well as bad debt risks in […]

General

It’s Not Always Management’s Fault

When a share price underperforms the market, how much of that can be blamed on management? Conversely, when prices surge higher, how much credit do the senior execs deserve? Of course, in the short run, the answer is probably ‘not much’. But even over a period of a year or two it can be hard to connect executive decisions to […]

General

A Business Unclear

I was fortunate enough to join Luke Winchester (aka Wini) from Merewether Capital on Ausbiz last week, and he made a rather good point. Well, he made many, but the following stood out to me. To paraphrase: “If you can’t easily figure out exactly what a business does, it’s usually best to move on.” It’s a good heuristic. Right up there […]